Showing results (61-70 of 72) with videos related to
Sort By:
Pageof 8
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 1994
Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptidesG Y Ishioka, L Adorini, J C Guery, et al.Pharmaceutical Research|September 1, 1993
Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serumM F Powell, T Stewart, L Otvos, et al.Vaccine|June 1, 1997
Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulationsM J Newman, J Y Wu, B H Gardner, et al.AIDS Research and Human Retroviruses|January 1, 1994
Development of a single-shot subunit vaccine for HIV-1J L Cleland, M F Powell, A Lim, et al.Journal of Pharmaceutical Sciences|January 1, 1996
Isomerization and formulation stability of the vaccine adjuvant QS-21J L Cleland, C R Kensil, A Lim, et al.Pharmaceutical Research|May 1, 1998
Stability of alkoxycarbonylamidine prodrugsZ Shahrokh, E Lee, A G Olivero, et al.AIDS Research and Human Retroviruses|February 1, 1995
Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigsM F Powell, D J Eastman, A Lim, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 15, 1993
HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactionsA Sette, J Sidney, C Oseroff, et al.AIDS Research and Human Retroviruses|January 1, 1994
Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboonsM F Powell, J L Cleland, D J Eastman, et al.Journal of Spinal Disorders|September 3, 1998
Torsional injury resulting in disc degeneration: I. An in vivo rabbit modelA G Hadjipavlou, J W Simmons, J P Yang, et al.Pageof 8